9 results
The aim of the study is to assess the efficacy and safety of the self-sizing RFA ballon for eradication of Barrett's mucosa with low-grade, high-grade and early neoplasia
The current study is designed to determine the most optimal treatment regimen for Barrett*s esophagus with early neoplasia, using the Self Sizing RFA balloon. In this study we will compare the standard ablation regimen (1x-clean-1x) with a…
The objective of this study is to perform a non-inferiority analysis of drug-eluting balloons (DEB) with provisional stenting and primary stenting with drug-eluting stents (DES) in the treatment of femoropopliteal arterial occlusive disease. If DEB…
The aim of this study is to determine whether LNP023 is effective and safe for the treatment of PNH. LNP023 is compared to the Standard of Care (SOC) anti-C5 antibody treatment. The primary objectives are to:• Demonstrate superiority of LNP023…
The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of iptacopan in patients with PNH and to provide access to patients who have completed the treatment extension period (without tapering down) of the Phase 2…
Primary objective adults:To demonstrate the superiority of iptacopan (200 mg b.i.d.) compared to placebo in reducing proteinuria at 6 months of treatment.The primary clinical question of interest is:What is the effect of iptacopan vs. placebo on log…
The purpose of the study is to evaluate the efficacy and safety of LNP023 compared to placebo on proteinuria reduction and slowing renal disease progression in primary IgAN patients
Participants enrolling from study CLNP023B12301 or CLNP023B12302• Primary Objective: To evaluate the long-term safety and tolerability of iptacopan in participants with C3G or IC-MPGN
The primary objective is to evaluate the long-term safety and tolerability of iptacopan in eligible participants. The primary clinical question of interest is: what is the long-term safety and tolerability of iptacopan in IgAN participants including…